ClinicaliQ Trial Snapshot
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer — Recruiting • Phase I • Oncology • NCT06190899.
- Treatment Being Tested: Gedatolisib (a PI3K/mTOR inhibitor) combined with darolutamide (an androgen receptor antagonist) in metastatic castration-resistant prostate cancer, with dose-finding and efficacy evaluation across Phase 1/2 stages.
- Patient Eligibility Overview: Men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed despite androgen deprivation therapy; specific inclusion/exclusion criteria determine suitability for randomization into dose cohorts.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.
Eligibility Snapshot
- Adult males ≥18 years of age 2. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate without a small cell component and with
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.